Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
Equillium, Inc. has gained Human Research Ethics Committee and Therapeutic Goods Administration approval in Australia to initiate its Phase 1 clinical trial of EQ504, a potent and selective AhR modulator designed to treat severe autoimmune and inflammatory disorders such as ulcerative colitis. The randomized, double-blind, placebo-controlled trial …